Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: We compared outcomes from a single-arm study of tisagenlecleucel with standard of care (SOC) regimens in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Methods: The analysis included one tisagenlecleucel study, one blinatumomab study, one clofarabine monotherapy study, three studies of clofarabine combination regimens and two studies of other salvage chemotherapy. Matching-adjusted indirect comparison analyses were conducted. Results: After adjusting for baseline characteristics, tisagenlecleucel was associated with significantly prolonged overall survival compared with blinatumomab (hazard ratio [95% CI], 0.32 [0.16–0.64]); clofarabine monotherapy (0.24 [0.13–0.42]); clofarabine combination regimens (0.26 [0.15–0.45]); two salvage therapies (0.15 [0.09–0.25] and 0.27 [0.15–0.49]). Conclusion: The analysis demonstrated tisagenlecleucel was associated with substantially greater survival benefit versus all SOC regimens.
Supplementary Material
File (suppl_file.zip)
- Download
- 80.54 KB
References
1.
Incidence of Childhood Leukaemia: Fact Sheet 4.1 (2019). www.euro.who.int/__data/assets/pdf_file/0005/97016/4.1.-Incidence-of-childhood-leukaemia-EDITED_layouted.pdf
2.
Siegel DA, Henley SJ, Li J, Pollack LA, Van Dyne EA, White A. Rates and trends of pediatric acute lymphoblastic leukemia – United States, 2001–2014. MMWR Morb. Mortal. Wkly Rep. 66(36), 950–954 (2017).
3.
Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120(14), 2807–2816 (2012).
4.
Von Stackelberg A, Volzke E, Kuhl JS et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. Eur. J. Cancer 47(1), 90–97 (2011).
5.
Ko RH, Ji L, Barnette P et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J. Clin. Oncol. 28(4), 648–654 (2010).
6.
Tallen G, Ratei R, Mann G et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J. Clin. Oncol. 28(14), 2339–2347 (2010).
7.
Parker C, Waters R, Leighton C et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376(9757), 2009–2017 (2010).
8.
Nguyen K, Devidas M, Cheng SC et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 22(12), 2142–2150 (2008).
9.
Rheingold SR, Ji L, Xu X et al. Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study [abstract]. J. Clin. Oncol. 37(Suppl. 15), 10008 (2019).
10.
Genzyme Corporation. CLOLAR. Clofarabine (2016). www.accessdata.fda.gov/drugsatfda_docs/label/2016/021673s025lbl.pdf
11.
European Medicines Agency. EVOLTRA (clofarabine) EPAR Summary for the Public (2015). www.ema.europa.eu/en/documents/overview/evoltra-epar-summary-public_en.pdf
12.
Jeha S, Gaynon PS, Razzouk BI et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J. Clin. Oncol. 24(12), 1917–1923 (2006).
13.
A Phase II, open-label study of clofarabine in paediatric patients with refractory/relapsed acute lymphoblastic leukaemia (2004). www.clinicaltrialsregister.eu/ctr-search/trial/2004-001853-27/results
14.
Amgen Inc. BLINCYTO. Blinatumomab (2018). www.accessdata.fda.gov/drugsatfda_docs/label/2018/125557s013lbl.pdf
15.
Amgen receives FDA breakthrough therapy designation for investigational BiTE® Antibody blinatumomab in acute lymphoblastic leukemia (2014). http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=1944069
16.
Brischwein K, Parr L, Pflanz S et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30(8), 798–807 (2007).
17.
Von Stackelberg A, Locatelli F, Zugmaier G et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34(36), 4381–4389 (2016).
18.
Kantarjian H, Stein A, Gokbuget N et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376(9), 836–847 (2017).
19.
Novartis Pharmaceuticals Corporation. Kymriah. Tisagenlecleucel (2018). www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma
20.
Novartis Europharm Limited. Kymriah. Tisagenlecleucel (2018). www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel
21.
Novartis Pharmaceuticals Canada Inc. Kymriah (tisagenlecleucel). Health Canada Product Monograph (2018). www.newswire.ca/news-releases/novartis-receives-health-canada-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleuceli-692581041.html
22.
KymriahTM, Zellsuspension zur Infusion (Tisagenlecleucelum) (2018). www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/kymriahtm_zellsuspensionzurinfusiontisagenlecleucelum.html
23.
Novartis Pharmaceuticals Australia Pty Ltd. Kymriah (tisagenlecleucel). Australian Prescribing Information (2018). www.nps.org.au/assets/p30-New-drug-2-Tisagenlecleucel-v2.pdf
24.
Maude SL, Laetsch TW, Buechner J et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378(5), 439–448 (2018).
25.
Laetsch TW, Myers GD, Baruchel A et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 20(12), 1710–1718 (2019).
26.
Signorovitch JE, Sikirica V, Erder MH et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940–947 (2012).
27.
NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE (2017). http://nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSD-FINAL.pdf
28.
Thom H, Jugl SM, Palaka E, Jawla S. Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals. Value Health 19(3), A1–A318 (2016).
29.
Engauge Digitizer Software (2018). http://markummitchell.github.io/engauge-digitizer
30.
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).
31.
Maude SL, Pulsipher MA, Boyer MW et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood 128(22), 2801 (2016).
32.
Maude SL, Teachey DT, Rheingold SR et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. J. Clin. Oncol. 34(Suppl.15), (2016). https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3011
33.
Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371(16), 1507–1517 (2014).
34.
Grupp SA, Maude SL, Rives S et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukemia. Blood 132(Suppl. 1), 895 (2018).
35.
Hijiya N, Gaynon P, Barry E et al. A multi-center Phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 23(12), 2259–2264 (2009).
36.
O'Connor D, Sibson K, Caswell M et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 154(4), 482–485 (2011).
37.
Locatelli F, Zugmaier G, Vora A et al. Blinatumomab use in pediatric patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from an open-label, multicenter, expanded access study. J. Clin. Oncol. 35(1 Suppl. 15), 10530 (2017).
38.
Hijiya N, Thomson B, Isakoff MS et al. Phase II trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 118(23), 6043–6049 (2011).
39.
Locatelli F, Testi AM, Bernardo ME et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br. J. Haematol. 147(3), 371–378 (2009).
40.
Miano M, Pistorio A, Putti MC et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leukemia Lymphoma 53(9), 1693–1698 (2012).
41.
Kuhlen M, Willasch AM, Dalle JH et al. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. Br. J. Haematol. 180(1), 82–89 (2018).
Information & Authors
Information
Published In
Pages: 849 - 860
PubMed: 32602756
Copyright
© 2020 Qiufei Ma. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 2 May 2020
Accepted: 15 June 2020
Published online: 30 June 2020
Keywords:
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0069
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Samuel John, Kevin J. Curran, Erin M. Hall, Amy K. Keating, Susanne H.C. Baumeister, Sarah Nikiforow, Timothy Driscoll, Amy Moskop, Kevin O. McNerney, Christine L. Phillips, Michael A. Pulsipher, Emily M. Hsieh, Rayne H. Rouce, Marcelo C. Pasquini, Ranjan Tiwari, Jennifer Willert, Roberto Ramos, Joerg Krueger, Erin Guest, Stephan A. Grupp, Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry, Blood Advances, 10.1182/bloodadvances.2025015881, 9, 20, (5249-5262), (2025).
- Arend v. Stackelberg, Katja Jäschke, Etienne Jousseaume, Corinna Templin, Ulli Jeratsch, Daniela Kosmides, Ingo Steffen, Nicola Gökbuget, Christina Peters, Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, Leukemia, 10.1038/s41375-023-02042-4, 37, 12, (2346-2355), (2023).
- Muayad Alali, James G Carlucci, John Christenson, Cassandra Prather, Jodi Skiles, Case Series of False-Positive HIV Test Results in Pediatric Acute Lymphoblastic Leukemia Patients Following Chimeric Antigen Receptor T-Cell Therapy: Guidance on How to Avoid and Resolve Diagnostic Dilemmas, Journal of the Pediatric Infectious Diseases Society, 10.1093/jpids/piac028, 11, 8, (383-385), (2022).
- Michael R. Verneris, Qiufei Ma, Jie Zhang, Amy Keating, Ranjan Tiwari, Junlong Li, Hongbo Yang, Abhijit Agarwal, Lida Pacaud, Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia, Blood Advances, 10.1182/bloodadvances.2020004045, 5, 23, (5387-5395), (2021).
- Rahul Banerjee, Bita Fakhri, Nina Shah, Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome, Leukemia & Lymphoma, 10.1080/10428194.2021.1924370, 62, 11, (2600-2611), (2021).
- Shiho Wakase, Takanori Teshima, Jie Zhang, Qiufei Ma, Yoko Watanabe, Hongbo Yang, Cynthia Z. Qi, Xinglei Chai, Yanwen Xie, Eric Q. Wu, Ataru Igarashi, Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan, Transplantation and Cellular Therapy, 10.1016/j.jtct.2020.12.023, 27, 3, (241.e1-241.e11), (2021).